Cellectis
Manufacturing · France · 201-500 Employees
View Company Info for Free
Overview
Headquarters
8 Rue De La Croix Jarry, Paris, Ile-de-F...Phone Number
+33 181691600Website
www.cellectis.comRevenue
$75.3 MillionStock Symbol
ALCLSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Cellectis
Cellectis is a biopharmaceutical company founded in 1999 and headquartered in Paris, France. The company specializes in developing innovative pharmaceutical products and therapies. As a publicly traded organization since 2019, Cellectis focuses on manufacturing pharmaceuticals with operations across Europe and North America. The company maintains a strong presence in both B2B and B2C markets, leveraging mobile applications as part of their technology infrastructure.Explore more
Cellectis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellectis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cellectis has recently received funding, and reach out quickly before it becomes old news!
Check out if Cellectis is spiking on competitors!
Click to see if Cellectis had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Cellectis has new funding data
Earning: See what the market has to say on Cellectis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Cellectis
Product Launch: Get notified when Cellectis launches new products
Cellectis, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Cellectis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellectis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellectis.
Cellectis financials insights
Gather financial insights about Cellectis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Corporate Investment
$22.2M
2015
Stock Offering
$129M
2018
Stock Offering
$163.7M
Other Financing Round
$164M
2022
Debt
$42.6M
Cellectis Tech Stack
A closer look at the technologies used by Cellectis
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Award
Person-Based
Pharmaceuticals
Person-Based
Medical Research
Person-Based
Medical Research
Cellectis News & Media
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study eCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatmenCellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA) annual congress, on June 11-14, 2026, in Stockholm, Sweden.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellectis
Sign Up For FreeTo access detailed company insights
Cellectis is a biopharmaceutical company founded in 1999 and headquartered in Paris, France. The company specializes in developing innovative pharmaceutical products and therapies. As a publicly traded organization since 2019, Cellectis focuses on manufacturing pharmaceuticals with operations across Europe and North America. The company maintains a... Read More
